Speciality Medicines IPO

Speciality Medicines IPO Details

The Speciality Medicines IPO is a book-built issue of ₹29.14 crore, consisting entirely of a fresh issue of 0.24 crore shares. The price band of ₹117 to ₹124 per share and the lot size for an application is 1,000. The company filed its DRHP with SEBI on Sep 29, 2025.

The IPO will open for subscription from March 20 to 24, 2026, on the BSE SME platform with a tentative listing date fixed as March 30, 2026. The book-running lead manager (BRLM) for this issue is Unicon Capital Services Pvt. Ltd., while the registrar to the issue is Skyline Financial Services Pvt. Ltd.

Speciality Medicines IPO Date & Timeline

The Speciality Medicines IPO is officially set to open for subscription on March 20, 2026 and will close on March 24, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on Sep 29, 2025 and has now finalized its schedule following SEBI approval. Once the subscription window closes, the finalization of the basis of allotment is expected on Mar 25, 2026. Following this, the company will initiate refunds and credit shares to successful investors' demat accounts on March 27, 2026. Finally, the Speciality Medicines Ltd. shares are tentatively scheduled to list on the stock exchanges on Mar 30, 2026.

Speciality Medicines IPO GMP (Grey Market Premium)

“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.

The Speciality Medicines IPO GMP is currently trading at ₹[.], reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹[.], which is [.]% above the issue price. While the Grey Market Premium is a key indicator of demand and investor desire, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.

Company Background

Speciality Medicines Ltd. was incorporated as a private firm on February 5, 2021, in Ahmedabad. It transformed into a public limited company on June 25, 2024, to meet its expanding footprint in the pharmaceutical industry. Starting from a local startup with its headquarters in Gujarat and a corporate office in Mumbai, it has become a global player in the pharmaceutical industry with its current business operations in the marketing and distribution of specialized finished formulations in both domestic and international markets.

Operations & Product Range

Speciality Medicines Ltd. operates primarily as a marketer and distributor of specialty pharmaceutical products. It has a wide range of high-cost medicines that are orally administered and injected into the system for treating various complex and chronic medical conditions. Its medicines cover a wide spectrum of pharmaceutical classes such as oncology, immunology, neurology and rare diseases. It has a wide customer base ranging from government and private hospitals to overseas distributors.

Facilities & Capacity

Speciality Medicines Ltd. is a distribution-led organization that has developed an infrastructure to support a global supply chain. They source their products from manufacturers who operate to global standards, including WHO-GMP-certified facilities. A major part of their future strategy is to set up a separate R&D center. This new facility will include construction, lab machinery and electrical equipment to enhance their capabilities.

Brands & Market Presence

Speciality Medicines Ltd. has already established a strong footprint, as it currently operates in more than 20 states and also operates in more than 35 countries. Its main goal is to provide high-quality Indian medicine brands and registered specialty pharmaceuticals. Its main principle is to develop strong relationships with suppliers, providing high-quality medicine that adheres to high safety and efficacy standards. Its product range currently comprises 128 items, while plans are underway to increase this number to 281 products shortly.

Revenue Streams & Business Model

The major way to generate revenues for Speciality Medicines Ltd. is by trading and distributing the formulations. The business model for Speciality Medicines Ltd. is based on being a GDP-certified distributor and bringing the manufacturer and healthcare providers together. The working capital requirement for the company was ₹740.58 lakhs, but this has increased substantially to ₹3,121.44 lakhs by FY25.

Management & Shareholding

Speciality Medicines Ltd. is headed by its promoters, Parth Goyani and Sumit Goyani. Before the issue of the IPO, the average cost of acquisition of equity shares of the company belonging to promoters stood at ₹6.82 for Parth Goyani and ₹6.97 for Sumit Goyani. There is a change in the shareholding structure with the issue of fresh shares, which is a portion of the post-issue paid-up equity share capital.

Board & Key Management

The board and key management group of Speciality Medicines Ltd. consists of the Chairman and Managing Director, Parth Goyani. The company also has a Whole-Time Director, Sumit Goyani. The company has a professional management group as well, which includes CFO Kalpesh Bharatbhai Pipaliya, CS named Anita Kumawat, who also acts as the Compliance Officer. The company also has Independent Directors for the purpose of corporate governance.